TBAJ-587

Research use only, not for human use.

TBAJ-587 is a potent anti-tuberculosis agent. TBAJ-587 inhibits M.tb strain H37Rv growth with MIC90s of 0.006 and <0.02 μg/mL in MABA and LORA assay respectively. BAJ-587 has more potent activity against M. tuberculosis and better efficacy in animal models of TB.

TBAJ-587 is a potent anti-tuberculosis agent. TBAJ-587 inhibits M.tb strain H37Rv growth with MIC90s of 0.006 and <0.02 μg/mL in MABA and LORA assay respectively. BAJ-587 has more potent activity against M. tuberculosis and better efficacy in animal models of TB.

Bedaquiline is adrug of the diarylquinoline class that has proven to be clinically effective against drug-resistant tuberculosis, but has a cardiac liability due to its potent inhibition of the cardiac potassium channel protein hERG. TBAJ-587, an analogue of Bedaquiline, demonstrates more potent anti-tubercular activity, with greatly attenuated hERG blockade. TBAJ-587 inhibits hERG channel with an IC50 of 13 μM.

——

——

Microbiology/Virology

Antibiotic

tuberculosis

——

——

2252316-16-6

614.5

C30H33BrFN3O5

>98% (HPLC)

In Vitro:?DMSO : 43.33 mg/mL (70.51 mM)

COc1cc(cc(OC)n1)C(O)(CCN(C)C)C(c1cccc(OC)c1F)c1cc2cc(Br)ccc2nc1OC

——

(-20℃)

With Ice Pack

≥ 2 years